7Relapsing polychondritis
Section snippets
History
The first case of relapsing polychondritis (RP) was reported in 1923 by Jaksch-Wartenhorst who called it ‘polychondropathy’.1 He described a 32-year-old male patient who presented with fever, asymmetric polyarthritis, pain, swelling and deformity of the ears and nose, as well as stenosis of the external auditory canals which resulted in diminished hearing. Biopsy of the nasal cartilage revealed loss of cartilage matrix and a hyperplastic mucous membrane. In 1960 Pearson et al reviewed 12 cases,
Epidemiology
The estimated annual incidence rate is 3.5/million in Rochester, Minnesota (personal observations by Michet and Luthra). The peak age for disease onset is the fifth decade, although cases have been reported in children as well as in the very elderly.3 RP is usually known to occur with equal frequency in both sexes; however, some authors found an increased prevalence among women. It seems to occur with equal frequency in all racial groups, but there are very few data available on non-Caucasian
Etiopathogenesis
The cause of polychondritis is unknown. At first it was suspected by Jaksch-Wartenhorst to be of degenerative origin, but since then several lines of evidence have accumulated to support the role of the immune system:
- •
frequent association with other autoimmune diseases
- •
CD4+ T lymphocytes, plasma cells, immunglobulins and complement are detectable in tissue lesions
- •
presence of autoantibodies to type II, IX and XI collagens, and other cartilage proteins, including matrilin-1 and cartilage oligomeric
Clinical features
Disease onset is usually sudden and flagrant, with characteristic clinical signs. Table 3 summarizes the clinical features of patients with RP in four large series and a small case series reported in the literature.3., 6., 12., 25., 26. Non-specific initial symptoms such as fever, weight loss, fatigue or lethargy may also be present and delay the diagnosis significantly if no characteristic clinical signs are seen.
Auricular chondritis is present in almost all patients, involving the
Diagnosis and investigations
The diagnosis of RP is usually easy, based on characteristic clinical manifestations. Empirical diagnostic criteria (Table 4), originally proposed by McAdam et al25, were later modified by Michet et al3 and Damiani.34 Patients may sometimes be diagnosed after a significant delay from the onset of the disease if initial symptoms are non-specific. Moreover, many conditions can mimic the initial features, or an associated disorder may confuse the clinical pattern.
Laboratory findings in RP are
Differential diagnosis
Other types of chondritis and perichondritis should be ruled out. Infectious diseases—including acute streptococcal or fungal infection, leprosy and syphilis—may also lead to perichondritis. These conditions, as well as tuberculosis, Wegener's granulomatosis or lethal midline granuloma, may cause nasal damage, also a feature of RP. Auricular involvement must be differentiated from traumatic and chemical conditions, such as frostbite and insect bite. Unilateral auricular chondritis alone may be
Management
Treatment has primarily been symptomatic in RP. Non-steroidal anti-inflammatory drugs alone are adequate for patients with mild auricular or nasal chondritis and/or arthralgia in some patients. More serious manifestations, including acute polychondritis, laryngotracheal or ocular symptoms, or systemic vasculitis, require corticosteroids, prednisone or equivalent in doses of 0.5–1 mg/kg of body weight per day. Higher-dose oral steroids or even intravenous pulse therapy in doses of 1000 mg/day
Prognosis
RP generally shows an intermittent but progressive course. Sites of involvement, the severity of inflammation, inner organ manifestations and response to therapy are unpredictable. Eventually, most patients develop some degree of disability which may include hearing or visual impairment, phonation difficulties or cardiorespiratory problems. Musculoskeletal complications in RP, if not associated with RA, are rare. The life expectancy of patients with RP is reduced: earlier studies indicated
Summary
RP is a rare disorder occurring at nearly all ages. Its etiopathogenesis is still unknown, and diagnosis and monitoring are based on clinical symptoms. However, recent findings indicate that cartilage constituents, including CII and matrilin-1, in genetically susceptible individuals may trigger the autoimmune response leading to cartilage destruction. Cartilage degradation products such as urinary type II collagen neoepitope may be suitable for monitoring disease activity and response to
Acknowledgements
The authors thank Dr A. Judák (National Institute of Rheumatology and Physiotherapy, Budapest) for the photos of her patient with relapsing polychondritis.
References (49)
- et al.
Relapsing polychondritis. Immunomicroscopic findings in cartilage of ear biopsy specimens
Human Pathology
(1980) - et al.
Ocular and systemic findings in relapsing polychondritis
Ophthalmology
(1986) - et al.
Relapsing polychondritis: a clinical review
Seminars in Arthritis and Rheumatism
(2002) Neurologic manifestations of connective tissue disease
Neurologic Clinics
(2002)- et al.
Composition of urinary glycosaminoglycans in a patient with relapsing polychondritis
Clinical Biochemistry
(2002) - et al.
Endobronchial ultrasonography in the diagnosis and treatment of relapsing polychondritis with tracheobronchial malacia
Chest
(2003) - et al.
Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals
Rheumatic Disease Clinics of North America
(1995) - et al.
Anti-CD4 monoclonal antibody for relapsing polychondritis
Lancet
(1991) Polychondropathy
Wiener Archiv für Innere Medizin
(1923)- et al.
Relapsing polychondritis
New England Journal of Medicine
(1960)
Relapsing polychondritis. Survival and predictive role of early disease manifestations
Annals of Internal Medicine
Relapsing polychondritis. A clinical, pathologic-anatomic and histochemical study of 2 cases
Acta Pathologica et Microbiologica Scandinavica
Relapsing polychondritis
Annals of Internal Medicine
Cell-mediated immunity to cartilage proteoglycan in relapsing polychondritis
Clinical and Experimental Immunology
Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis
Arthritis and Rheumatism
Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis
Journal of Rheumatology
Lack of association of HLA-A and B locus antigens with relapsing polychondritis
Tissue Antigens
Susceptibility to relapsing polychondritis is associated with HLA-DR4
Arthritis and Rheumatism
Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients
Journal of Rheumatology
Autoantibodies to cartilage collagens in relapsing polychondritis
Archives of Dermatological Research
Specificity of antibodies to type II collagen in rheumatoid arthritis
Arthritis and Rheumatism
Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse
Arthritis and Rheumatism
The matrilins: a growing family of A-domain-containing proteins
Biochemical Society Transactions
The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis
Arthritis and Rheumatism
Cited by (111)
Erythromelalgia. Part II: Differential diagnoses and management
2024, Journal of the American Academy of DermatologyRelapsing polychondritis: prevalence of cardiovascular diseases and its risk factors, and general disease features according to gender
2017, Revista Brasileira de ReumatologiaDiagnostic Pathology: Head & Neck
2017, Diagnostic Pathology: Head and NeckRelapsing Polychondritis
2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth EditionRelapsing polychondritis with severe hearing loss
2015, Revista Brasileira de Reumatologia